Related Experiment Video

Updated: Mar 30, 2026

An In Vitro Dissolution Determination of Multi-Index Components in Tibetan Medicine Rhodiola Granules
05:59

An In Vitro Dissolution Determination of Multi-Index Components in Tibetan Medicine Rhodiola Granules

Published on: November 4, 2022

2.2K

[Discussion about risk and management of Chinese patent medicine with double identity]

Yun Jin, Sai-wei Wu, Xing-wang Gao

    Zhongguo Zhong Yao Za Zhi = Zhongguo Zhongyao Zazhi = China Journal of Chinese Materia Medica
    |November 11, 2015
    PubMed

    More Related Videos

    HPLC Coupled with Chemical Fingerprinting for Multi-Pattern Recognition for Identifying the Authenticity of Clematidis Armandii Caulis07:29

    HPLC Coupled with Chemical Fingerprinting for Multi-Pattern Recognition for Identifying the Authenticity of Clematidis Armandii Caulis

    Published on: November 11, 2022

    2.6K
    Author Spotlight: Integrating 2D-HPLC-MS and Molecular Networking in Natural Medicine Analysis07:50

    Author Spotlight: Integrating 2D-HPLC-MS and Molecular Networking in Natural Medicine Analysis

    Published on: December 8, 2023

    1.3K

    Related Concept Videos

    Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence01:19

    Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

    Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
    225
    Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

    Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

    Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
    216
    Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

    Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

    Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
    243
    Bioequivalence of Drugs: Drugs with Multiple Indications01:09

    Bioequivalence of Drugs: Drugs with Multiple Indications

    The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
    217